Hao-Fountain Syndrome: 32 novel patients reveal new insights into the clinical spectrum

Updating the clinical spectrum of HAFOUS

Moritz Claudius Wimmer[1] (moritz.wimmer@med.uni-heidelberg.de),

Heiko Brennenstuhl[1] (heiko.brennenstuhl@med.uni-heidelberg.de),

Steffen Hirsch[1] (steffen.hirsch@med.uni-heidelberg.de),

Laura Dötsch[1] (laura.doetsch@med.uni-heidelberg.de),

Samy Unser[1] (samy.unser@med.uni-heidelberg.de),

Pilar Caro[1] (MariadelPilar.CaroMartin@med.uni-heidelberg.de),

Christian Patrick Schaaf[1,2] (christian.schaaf@med.uni-heidelberg.de)

[1]Institute of Human Genetics, Heidelberg University, Heidelberg

[2]Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA

Correspondence:

Christian Patrick Schaaf, Institute of Human Genetics, University of Heidelberg, Im Neuenheimer Feld 366, D-69120 Heidelberg, Germany

christian.schaaf@med.uni-heidelberg.de

Ethical statement:

This study was performed under the research protocol H-34578, approved by the Institutional Review Board for Baylor College of Medicine and Affiliated Hospitals. All individuals and their guardians were informed and provided consent for the study.

Statement of contribution:

Methodology: MCW, HB; Investigation: MCW, LD, PC; Validation: SH, SU; Project administration: MCW, PC; Writing – original draft: MCW; Writing – review and editing: CPS, MCW; Visualization: HB, MCW; Supervising: CPS

Acknowledgments:

The authors thank the individuals and the families with Hao-Fountain syndrome, who have provided clinical data and overwhelming support for our efforts. The authors also thank Ferdinand Althammer and Jannis Bücking for comments that greatly improved the manuscript.

Conflicts of interest:

The authors declare no competing interests.

Data Availability statement:

Abstract

Hao-Fountain syndrome (HAFOUS, OMIM: #616863) is a neurodevelopmental disorder
caused by pathogenic variants in the gene *USP7* coding for USP7, a protein involved in
several crucial cellular homeostatic mechanisms and the recently described MUST complex.
The phenotype of HAFOUS is insufficiently understood, yet there is a great need to better
understand the spectrum of disease, genotype-phenotype correlations, and disease
trajectories.

We now present a larger cohort of 32 additional individuals and provide further clinical
information about six previously reported individuals. A questionnaire-based study was
performed to characterize the phenotype of Hao-Fountain syndrome more clearly, to
highlight new traits, and to better distinguish the disease from related neurodevelopmental
disorders. In addition to confirming previously described features, we report hyperphagia
and increased body weight in a subset of individuals. HAFOUS patients present an increased
rate of birth complications, congenital anomalies, and abnormal pain thresholds. Speech
impairment emerges as a potential hallmark of Hao-Fountain syndrome. Cognitive testing
reports reveal borderline intellectual functioning on average, although some individuals
score in the range of intellectual disability.

Finally, we created a syndrome-specific severity score. This score neither indicates a sex- nor
age-specific difference of clinical severity, yet highlights a more severe outcome when amino
acid changes colocalize to the catalytic domain of the USP7 protein.

Keywords
USP7, Hao-Fountain syndrome, neurodevelopmental disorder, rare disease, clinical
spectrum, genotype-phenotype association

Introduction

Ubiquitin-specific protease 7 (USP7), also known as Herpesvirus-associated protease (HAUSP), plays a crucial role as a regulator of ubiquitination in genome stability pathways[1]. Recently, it was also described to contribute to the MUST pathway, which regulates intracellular protein trafficking and recycling[2,3]. Another protein involved in this pathway, MAGEL2, is associated with Schaaf-Yang (SYS, OMIM #615547)[4] and Prader-Willi syndromes (PWS, OMIM #176270)[5], and USP7 haploinsufficiency was subsequently shown to also cause a neurodevelopmental disorder[3,6]. The initial report included seven individuals, six cases with genomic deletions containing the *USP7* gene and one individual with a *USP7* nonsense mutation[3]. Patients presented with developmental delay (DD), autism spectrum disorder (ASD), seizures, a behavioral phenotype, and signs of hypogonadism. Intriguingly, this clinical presentation shows great overlap with PWS and SYS by neurodevelopmental delay, failure to thrive, endocrine disruptions, behavioral anomalies, and muscular hypotonia[5,7-9].

To date, the largest cohort of patients affected by Hao-Fountain Syndrome (HAFOUS, OMIM: #616863) was presented by Fountain et al. in 2019 describing 16 novel patients[6]. The consistency of symptoms, regardless of the underlying variant type, supported the concept of USP7 haploinsufficiency as the causal factor of the disorder. Individuals presented with DD/ID, eye anomalies, feeding difficulties, GERD, behavioral anomalies, and ASD as the most frequent features. Furthermore, an in-depth secondary analysis of brain MRI images revealed various morphological anomalies with white matter paucity as the most frequent finding, reflected by a significant reduction of thickness of both splenium and body of the corpus callosum[6].

In subsequent case reports, six more patients were added to the publicly available cohort[10-13]. These new cases implicate a higher variability of the clinical spectrum, as fetal complications[10,11], congenital heart defects[10], and isolated tubal torsion[12] were first described. Next to these specific items, the clinical presentation of these patients is mainly according to the phenotype described previously.

We here present 32 novel individuals with variants in *USP7* and provide further clinical information about six previously described patients with a first report on intellectual functioning, growth parameters, and pregnancy complications. Finally, by creating a severity score of clinical phenotype, we provide an outline of genotype-phenotype correlations.

Subjects and Methods

This study is based on a 12-page questionnaire sent to all families listed in the USP7 registry. This registry was built in cooperation with the Foundation for USP7-related Diseases (www.USP7.org), enrolment was based on genotype. We included all individuals with confirmed genetic variants affecting the *USP7* gene and categorized patients based on type of mutations. Variants, including cases from the literature, were standardized using Mutalyzer 3 (https://mutalyzer.nl) and re-classified according to the AMP/ACMG criteria[14]. The questionnaire used within this study was designed with the Foundation for USP7-related Diseases to capture previously unrecognized symptoms. It was conceived to be filled out by the parents and always contained the option to select "unknown" if reporting was

impossible. Growth centiles and z-scores were calculated using an online tool based on CDC
standard values (https://www.pedz.de/en). Detailed clinical reports were requested,
especially brain imaging and EEG reports. The data presented in this study are primarily
based on parental reports. We endeavored to enhance the validation process by
incorporating clinical reports whenever feasible. It should be noted that results from testing
reports, radiological imaging reports, and behavioral assessments were accepted without
secondary evaluation. Thirty-eight families replied to the request and sent back at least the
questionnaire and a genetic testing report, accompanied by a consent form. Six of those
patients had been previously reported by Fountain et al. in 2019[6]. We labeled the cases
based on their chronological appearance in the literature and therefore report individuals
#30 to #61 (*Supplemental table 1*).
If not stated otherwise, the frequency of the symptoms always describes the prevalence in
all publicly accessible cases, including patients described by Hao et al., Fountain et al., Capra
et al., Zampieri et al., Zheng et al., and the participants of this study[3,6,10,12,13].
A severity score was developed based on the most frequently occurring clinical features.
Where available, the score considers the range of severity, e.g., one or two points based on
the severity of the developmental delay. A scale of 0 to 24 points was assigned and
normalized afterwards to avoid bias by data availability. The exact procedure next to the
calculation of individual severity scores can be seen in the supplemental material
(*supplemental methods, supplemental table 14*). Severity scores were calculated exclusively
for participants of our study. The categorization of patients with a missense variant, as
described below, was conducted based on the protein domain boundaries outlined by Valles
et al. in 2020[1].
Differences between two groups for the severity index were evaluated using Student's t test.
Whenever comparing more than one group for continuous variables (developmental
milestones, growth parameters), a one-way ANOVA analysis was performed. One-sample t
tests were performed in a z-normalized setting to assess deviation from the average
population. Analyses were conducted using GraphPad (Version 9.5.1) or R (R Core Team,
Vienna, Austria), and data for all patients were collected in IBM SPSS Statistics 29.
144
145

Results
We present 32 novel patients (16 M/16 W) with an average age of 9.97 years (2-20 years).
All individuals harbor variants affecting *USP7* (two whole-gene deletions, three partial gene
deletions, one intragenic deletion, six truncating variants, 15 missense variants, and five
splice-site variants) (*Table 1*). Figure 1 illustrates the distribution of missense and nonsense
variants, revealing an enrichment of missense variants within the catalytic domain. Notably,
no N-terminal nonsense variants were reported. The symptom reported most frequently is
motor developmental delay, reflected by an overall delay in attainment of developmental
milestones, followed by motor impairment, gait abnormalities, and muscular hypotonia.
Furthermore, autism spectrum disorder (ASD), communication deficits, an abnormal pain
threshold, gastrointestinal issues, and brain MRI anomalies are typical features presented by

more than two-thirds of the cohort analyzed in this study. A summary of the most frequent
symptoms is provided in *Table 2*, and a deeper analysis of all assessed symptoms subdivided
by genotype can be found in the supplemental material (*Supplemental Tables 1-13*).
160
Growth parameters
Growth parameters from 39 patients indicate a trend towards increased height, weight, and
BMI, with BMI achieving a statistically significant level (one sample t test; p_{BMI}= 0,0377).
Among the entire cohort, the mean weight measures at the 59th centile, the mean body
height measures at the 60th centile, and the mean BMI (18.84) lies within the 61st centile
(*Figure 1, Table 3*). For 34 total cases, we could analyze an age-adjusted BMI percentile. One
case is below the 5th centile indicating underweight as defined by the CDC[15], 22 cases are in
the average weight range, six fall in the overweight range, and five fulfill obesity criteria.
Therefore, 32 % of our entire cohort are overweight or obese. Although there is no general
trend towards growth retardation, 13 % (6/48) of this patient cohort indicate short stature,
defined as a body size at least two standard deviations below an age-adjusted standard
population[16]. Furthermore, 14 of 43 (33 %) patients showed small hands, while 19 of 46 (41
%) showed small feet, in both cases defined as feet and hand length below the age-adjusted
25th percentile (for novel cases).
175
Pregnancy and birth
Contrary to the body measurements described above, patients demonstrated a trend
towards reduced birth weight and body size. Average birth weight is at the 42nd centile, and
mean birth size at the 47th (*Figure 1, Table 3*). Neither sex nor genotype appear to influence
growth parameters or birth body measurements (*Supplemental Figures 1-3*). Interestingly,
we see both a subgroup being small for gestational age (birth weight below the 10th centile)
and one being large for gestational age (birth weight above the 90th centile). The former
criterion is met in 8 of 37 cases (22 %), the latter in six of 37 cases (16 %).
Neonatal muscular hypotonia affected a majority of 25 out of 44 individuals (57 %). Head
circumference measures at the gestational age-adjusted 47th centile and does not indicate
altered head circumference at birth. A single patient (3%) manifested hydrocephalus as an
infant. Twenty of 38 parents surveyed (53%) reported problems during pregnancy, which
ranged from common pregnancy-related issues such as gestational diabetes to detected
cardiac peculiarities or polyhydramnios. Decreased fetal movement was reported in seven of
44 cases (16 %). While preterm delivery occurred in eight of 40 cases (20 %), the mean
gestational age was 37.77 weeks. 15 of 37 parents (41 %) reported complications after
delivery and described those in a free-text answer, at which temperature instability was
named most often (five times), followed by severe jaundice (four times) and respiratory
distress (three times). Described congenital malformations met the criteria of having
significant medical, social, or cosmetic consequences for the affected individual in 14 of 34
cases (41 %). After the first case of a HAFOUS patient with congenital anomalies was
described by Capra et al. in 2019, we can now add 12 more individuals presenting anomalies
of the cardiac system (four times), the motor system (3 times), dysmorphisms of the head (3

times), malformation of the oral cavity or pharynx (3 times), and one patient born with a
duplex pelvicalyceal system in the right kidney.

Given the disparities between current body measurements and those taken at birth, our aim
was to explore the potential positive correlation between age and body weight, height, and
BMI. Surprisingly, we observed a noteworthy decline in body weight and BMI percentiles as
age increased (Supplemental Figure 4, A-C). Nevertheless, in our cohort and in line with the
general population, absolute BMI values exhibit a positive correlation with age
(Supplemental Figure 4D).

Developmental milestones
According to WHO data, the first motor development milestone, "sitting without support," is
reached after 6.0 months, while "hand-and-knees crawling" is reached after 8.5 months, and
"walking alone" can be accomplished after 12.1 months of life in the general population[17].
Presenting a delay at every motor development milestone, the cohort described here
reached free sitting on average after 11.7 months, crawling after 14.3 months, and free
walking after 26.6 months (*Table 3*). Twenty-six of 46 patients reached unsupported sitting
after more than 9.2 months, 14/27 patients reached crawling after more than 13.5 months,
and 39/47 patients reached free walking after more than 17.6 months. Each of these
mentioned time points represents the respective 99th centile in the general population.
Regarding speech developmental milestones, children are expected to speak their first word
at 18 months and can build the first two-words sentences 24 months after birth[18]. The
cohort described here spoke their first words on average after 21.1 months and built their
first two-word sentence after 32.9 months (*Table 3*). In this study, the oldest patient being
nonverbal was 14 years old and can also not safely walk without support (#43), while
Fountain et al. have already described a 20-year-old patient as nonverbal.

Intellectual ability
Fifteen families provided intellectual testing reports, which featured a full-scale intelligence
quotient in 10 cases and a description of severe ID in two cases (WISC or WPPSI testing
procedures). The mean FSIQ for this cohort is 78.3 (*Table 3*) and falls within the range of
borderline intellectual functioning. Nonetheless, two of 12 patients present an IQ below 35,
which defines severe intellectual disability (ID). Four of 12 patients score between 50 and 69,
indicating mild ID, two of 12 patients score between 70 and 85, indicating borderline
intellectual functioning, and another four patients show normal intellectual functioning with
an IQ above 85. The highest IQ measured in this cohort is 105. Two previously described
patients scored in the range of moderate ID [11,12].
According to previously published data, an extensive chart and questionnaire review
revealed signs of intellectual disability or (a history of) developmental delay in all cases.

Behavioral characteristics
Behavioral characteristics were stated to be a defining feature of HAFOUS and, therefore,
also queried meticulously in this study. Testing for autism spectrum disorder was conducted
in 15 cases, leading to a diagnosis in 10 cases (67 %). To overcome a selection bias, parents
were also asked to state whether their child showed autistic features. Thirty-one parents
reported positive testing or autistic behavioral features (72 %), while 12 neither tested
positive nor showed behavioral features indicative of autism. ASD is more prevalent than
initially expected in HAFOUS. Five of 21 parents reported an improvement of the autistic
features over time, eight of 21 saw a worsening, and eight of 21 could not observe any
change.
Nine of 42 reported an attention deficit hyperactivity disorder (ADHD) diagnosis (21 %),
another 12 of 42 described ADHD-like behavioral traits, but lack of a formal diagnosis (29 %),
and 21 of 42 did not observe any feature reminiscent of ADHD.
Previous publications indicated manifold behavioral traits, including aggressive behavior,
temper tantrums, impulsivity, compulsivity, stubbornness, and manipulative behavior.
Improving the objectivity of this assessment, we collected answers on a *Likert scale* for
different behavioral traits, which would typically not be expected to appear often. Defined
between 1 indicating "always" and five indicating "never", the scores ranged from 4.18
("destructive in her/his room") to 2.46 ("stubbornness"). Next to the latter, "impulsivity",
"overly social", and "physical contact seeking" scored values closer to always than never.
Previously described features like "aggressiveness" or "manipulative behavior" scored 3.46
and 3.95, respectively (*supplemental figure 5*). Therefore, we can only partially confirm the
previously described behavioral anomalies.
Furthermore, 10 of 29 parents reported general behavioral problems (34 %), 16 of 31
patients showed obsessive-compulsive behavior (52 %), and only 9 of 52 parents observed
skin picking (17 %).
268
Musculoskeletal phenotype
One of the most frequent symptoms of HAFOUS is hypotonia, prevalent in 42 of 53 patients
(79 %). Hypotonia improved over time in the vast majority of 23 out of 30 cases (worsened in
two cases, no change in 5 cases). This is surprising, given that hypotonia at the time of
examination is more prevalent than neonatal hypotonia, indicating a numerical increase of
cases, although the individual courses may be ameliorating on average. Aside from low
muscle tone, other dysfunctions of the muscular system can be observed. Abnormal gait was
reported in 31 of 47 individuals (66 %), and 23 of 35 exhibit balance unsteadiness (66 %).
Motor dysfunction affects all categories and is indicated by fine motor delay/impairment
(25/37, 68 %), gross motor delay/impairment (29/39, 74 %), as well as oral motor skills
delay/impairment (29/39, 76 %).
Less prevalent are scoliosis/kyphosis, which can be seen in 14 of 47 patients (30 %), and joint
contractures, reported by 11 of 45 affected families (24 %), most frequently located at the
lower extremity (6 cases).

Diverse dental issues were described by 20 of 36 parents (56 %), and the severity of the
issues ranges from severe malformations to cosmetic conspicuities. "Large front teeth" were
reported five times, while "deep palatal vault" and "supernumerary teeth" were reported
three times, respectively. Seventeen more issues were described no more than one time.
287
Neurological/ ophthalmological features
Eye anomalies were previously reported to affect a vast majority of HAFOUS patients. We
can confirm this for 28 of 53 patients in this cohort (53 %) and found farsightedness (10/34,
27 %) to appear most frequently (*supplemental table 5*).
One of the queried items proposed by the foundation was an abnormal pain threshold, a
known symptom of PWS[19]. We saw a high threshold for pain at 19 of 34 (56 %) patients and
a low threshold for pain at another seven of 34 (21%) patients, indicating 76 % with a
parent-reported dysfunctional pain threshold.
Although delayed speech development was described for HAFOUS previously and is
confirmed here, speech abilities at a later stage have never been described. 24 of 37 (65 %)
parents reported limited communication skills, being reflected both by reduced expressive
(26/38, 68 %) and receptive (23/36, 64 %) communication. Furthermore, parents were asked
which feature would be the most disabling symptom of their children and in 16 of all 38
questionnaires, parents reported speech problems as the most disabling feature,
highlighting the significance of this deficit for the affected individuals (cognitive impairment
named nine times, behavioral anomalies named eight times).
Hearing difficulties were reported in nine of 51 (18%) cases, and temperature instability was
reported in 14 of 34 (41 %) patients.
Fountain et al. extensively analyzed brain MRI reports in 2019, and we can mainly confirm
their findings based on the 13 new reports received. Combined with previously published
reports, brain MRIs exhibit anomalies of the ventricular system in 12 of 25 cases, signs of
white matter paucity/ small corpus callosum in 11/25 cases, simplified gyral patterns in 4/25
cases, white matter hyperintensities in 3/25 cases, vermian atrophy in 3/25 cases, and
hippocampal anomaly as well as a thick corpus callosum one time respectively. Summarizing
the reports, 23 of 34 (68 %) patients show any sign of abnormality described in their brain
MRI report with a wide variety of clinical significance as described above.
314
Seizures and sleep
Sleep disturbances were reported for 22 of 47 (47 %) patients and could partially explain the
frequent occurrence of fatigue (26/37, 70%) and a great need for rest (23/36, 64%). Sleep
apnea occurs in 10 of 34 (29 %) individuals.
Seizures were previously stated as a very prevalent and characteristic feature of HAFOUS. 23
of 57 (40 %) patients in the cohort described here were affected by seizures or have a history
of seizures; most effectively treated with anti-epileptic medications. The highest frequency
of seizures reported is 14 per year. Three of 32 (9 %) individuals had a febrile seizure. In
most cases, the reason for the seizures could not be clarified. Three of 19 (16 %) EEG reports
we received showed anomalies, in all three cases describing (probable) epileptic potential.

Ten parents provided information about the course of this symptom, and while four did not
observe any difference, six families confirmed an improvement concerning seizures over
time.

Gastrointestinal features
This cohort's most frequent gastrointestinal issues are constipation or diarrhea, affecting 29
of 52 (56 %) patients. Incontinence inappropriate for the individual's age was reported by 15
of 38 (39 %) parents. Gastroesophageal reflux disease can be observed in 18 of 49 (37 %)
cases, and five of 35 (14 %) parents reported jaundice beyond the neonatal period. In four of
38 (10 %) cases, gastrointestinal issues were described as the most disabling symptom.

Eating behavior
Abnormal eating behavior is one of the key features of PWS and, therefore, also of great
interest in HAFOUS research. 30 out of 54 individuals (56 %) in the cohort here experienced
feeding difficulties during infancy, closely associated with 15 of 51 (29 %) patients having
difficulties gaining weight. Eating difficulties can be observed in 16 of 36 (44 %) cases. For
the first time, we describe 14 of 36 (39 %) HAFOUS patients presenting hyperphagia. While
this parental assessment lacks objectivity, further behavioral characteristics like mouthing
behavior (10/34, 29 %) and chewing of inedible objects (10/37, 27 %) support this finding.
Furthermore, 23 % (3/13) of the children showing hyperphagia are obese, while only 5 %
(1/20) fulfill this criterion in the non-hyperphagic group. Manifestation of hyperphagia began
three times in the neonatal period (first month of life), four times in infancy (second month
until the end of the second year), five times in early childhood (three until eight years), and
once later than that.

Further physical characteristics
We also asked for endocrinological and respiratory dysfunction but could not identify any
features of high prevalence.
Hypothyroidism (1/21, 5 %), adrenal insufficiency (1/21, 5 %), and growth (GH) deficiency
(2/24, 8 %) were reported in only few patients, while hypogonadism was observed in 11 of
47 patients (23 %). We also included 4 of 16 boys with cryptorchidism/ micropenis.
Only a few patients depended on respiratory assistance in the form of intubation (2/35, 6 %)
or mechanical ventilation (3/35, 9 %). In 2 of 3 cases, chart review revealed that ventilation
was necessary immediately postnatally, while the context could not be outlined for one
further case. Asthma was prevalent in 8 of 36 (22 %) patients.
Eczema was described by 12 of 34 (35 %) parents.

Genotype-phenotype association
The cause of clinical heterogeneity in *USP7*-related disorder is not very well understood.
Aiming to overcome this issue, a severity score was developed as described before
(methods, supplemental methods). Anderson-Darling test (p=0.4699), Shapiro-Wilk test
(p=0.3424), and Kolmogorov-Smirnov test (p>0.1) were passed. Therefore, normal

distribution can be assumed (*supplemental figure 6A*). The mean severity score is 0.4937
(SD: 0.1561) for the 38 values we generated.
To better understand influencing factors on the severity, we compared both sexes and found
no difference (M: 0.49 SD 0.14, n:16; W: 0.50 SD 0.17, n:22) (*figure 2A). Furthermore, age
and type of the underlying genotype do not influence severity significantly (DEL: 0.47 SD
0.13, NON: 0.41 SD 0.12, MISS: 0.53 SD 0.18, SPLIC: 0.49 SD 0.07) (*figure 2B, supplemental
figure 6B*). Due to the heterogeneity of severity within the group harboring missense
variants, a correlation of exact position of the mutation and severity was investigated.
Missense mutations were grouped based on functionally relevant protein regions. A mean
value of 0.64 (n: 10) was found for the catalytic domain, 0.48 (n: 2) for the TRAF-like domain,
and 0.41 (n: 8) for the UBL-like domain, reflecting a significantly increased severity score for
mutations affecting the catalytic domain of USP7 (figure 2C, p = 0.0041).
Furthermore, to assess the predicted effect of missense variants, commonly used prediction
scores (CADD v1.6, M-CAP v.3.5a, REVEL v.3.5a21-23) were annotated for all biologically
possible USP7 missense variants and mapped onto a linearized representation of the USP7
protein, as previously demonstrated[20]. A generalized additive model was built using the
geom_smooth function of the R (R Core Team, Vienna, Austria) ggplot2 package to plot a
smoothened line and confidence interval (Supplemental Figure 7). Violin plots of
pathogenicity scores associated with all biologically possible missense variants falling into
either the catalytic domain, the TRAF-like domain or one of five Ubiquitin-like domains were
generated. Missense variants in catalytic domain are associated with statistically significant
higher pathogenicity scores shown by the assessment of three individual scores (REVEL,
MCAP, and CADD score) (Supplemental Figure 8).
389
Discussion
HAFOUS is a neurodevelopmental disorder leading to a variable clinical spectrum in terms of
occurrence and severity of symptoms. Speech and motor delay are most prevalent. Patients
typically present with communication deficits, muscular hypotonia, motor issues, abnormal
threshold for pain, and autism spectrum disorder. Complications during birth and congenital
anomalies are frequently present. Further symptoms such as seizures, hyperphagia, or
scoliosis only affect a subset of individuals. As previously proposed, this disorder can be
considered part of a disease family with SYS and PWS[21], showing a wide overlap of
symptoms between these disorders and a hypothesized shared path of pathophysiology via
the MUST complex[22]. Developmental delay, muscular hypotonia, reduced birth weight, and
infant feeding difficulties are shared features among these disorders[5,7].
Furthermore, endocrine dysfunction, also described as hypothalamic insufficiency, is a
crucial feature of SYS and PWS, but could not be seen frequently in our cohort[23,24]. ASD is
much more prevalent in HAFOUS and SYS (72 % and 78 %) compared to PWS (27 %)[7,25]. SYS,
with its unique prevalence of joint contractures and respiratory dysfunctions accompanied
by the most severe manifestation of developmental delay, intellectual disability, and
increased mortality, can be considered the most severe disorder within this disease family[7].
The causative factors need to be further investigated, but a neomorphic function of the

truncated MAGEL2 protein or a suppression of leaky expression from the maternal allele at
SYS was previously hypothesized to contribute to the alteration of manifestation between
these disorders[22]. HAFOUS positions itself as the least severe manifestation within this
disease family due to milder developmental delay, higher intellectual functioning, and
mostly an absence of endocrine dysfunctions (see[7,26,27]). Considering the MUST pathway as
one of the driving factors of these diseases, it is noteworthy to mention that pathogenic
variants in *USP7* were reported only heterozygous, suggesting the presence of wild-type and
variant USP7 proteins, while MAGEL2 mutations associated with PWS and SYS are
functionally hemizygous, suggesting the complete absence of wild-type MAGEL2. Therefore,
it can be presumed that mutations underlying SYS or PWS have a greater impact on the
functionality of the MUST complex than mutations causing HAFOUS. Nevertheless, the
variability of symptoms is intriguing, and some patients face a much more severe phenotype
than others. Although we provide data indicating the most severe phenotypes in patients
with missense variants within the catalytic domain, predicting the severity of phenotypes
based on individual mutations remains challenging.
423
This work sheds light on new, previously undescribed features of HAFOUS. Most remarkably,
we found an abnormal threshold for pain affecting 76 % of the cohort. Furthermore, we
describe some individuals presenting hyperphagia and potentially associated obesity.
Complications during pregnancy and congenital anomalies of varying severity had not been
reported previously. In addition to describing symptoms for the first time, we provide more
profound data for all previously described symptoms and observe a higher prevalence of
ASD than indicated by previous studies. Some features like seizures and particularly
aggressive and impulsive behavior are not as prevalent as initially hypothesized.
Developmental anomalies manifest in a variable trajectory of body weight, height, and BMI.
In contrast to the general population, we note slightly diminished birth height and weight,
with current body measurements reflecting a modest increase. However, there is a
discernible decrease in BMI and body weight with advancing age, suggesting an irregular and
atypical pattern of body growth.
437
Most significantly, we also analyzed genotype-phenotype correlations based on a developed
severity score and found increased severity scores for patients with a missense mutation
inside the catalytic domain of *USP7*, compared to those with a mutation outside the catalytic
domain. Evaluation of in silico scores revealed significant higher pathogenicity scores if
missense mutations occurred in the catalytic domain. Based on these results, we
hypothesize that missense variants within the catalytic domain of the protein are associated
with a more severe clinical phenotype compared to variants in the other parts of the protein.
We recommend analyzing larger cohorts even in the initial phase of investigating a novel
disease to ensure a reliable foundation of data. Our approach to include the disease
community when creating the questionnaire, appears helpful for gathering data on
previously undescribed features.

TRIM27 is another component of the MUST-complex and was not previously described in
case reports or systematic patient cohort analyses of neurodevelopmental disorders. This is
surprising as other proteins of this pathway can be assigned to various neurodevelopmental
conditions[22]. We currently aim to identify individuals carrying *TRIM27* variants to provide a
systematic analysis.
Interestingly, a recent paper implicates all the variable functions of USP7, but especially
contribution of USP7 to epigenetic transcriptional regulation, in the search for an etiology of
HAFOUS[28]. This seems reasonable to us as this group revealed that USP7 is highly associated
with histone ubiquitination on a transcriptional and posttranslational level as a silencer or
stabilizing partner for relevant factors of the PRC1 complex and therefore contributes to the
expression of several neurodevelopmental factors like AUTS2[28]. Establishing animal models
of this disorder could help understand the exact mechanism of pathophysiology and the
cellular pathways contributing to the phenotype. Remarkably, an overexpression mouse
model of *Usp7* presented altered dendritic arborization, neuronal migration, a behavioral
phenotype, and altered pain threshold, which is partially reminiscent of the phenotype
observed in our cohort suggesting dosage-sensitivity of Usp7 during neurodevelopment[29].
This study is subject to some limitations. The symptoms were recorded in a questionnaire by
interviewing the parents and are thus primarily subjective. Whenever possible, clinical charts
and records were assessed to ensure objectivity. Furthermore, the developed severity score
is limited by a detection bias, meaning that the objective nature of such scores always limits
the possible coverage of symptoms and individuality.
A phenotyping study of individuals at the University Hospital of Heidelberg is currently being
conducted to overcome this issue. By analyzing 32 novel and six previously described
patients, this study helps understand the clinical spectrum of HAFOUS, reveals undescribed
symptoms, and provides a first approach to a genotype-phenotype correlation. With this, we
intend to contribute to a more reliable and sound genetic consulting and prediction of
phenotype for affected individuals and families.
476

5 References

1.   Valles GJ, Bezsonova I, Woodgate R, Ashton NW. USP7 Is a Master Regulator of Genome Stability. *Front Cell Dev Biol*. 2020;8:717. doi:10.3389/fcell.2020.00717

2.   Hao YH, Doyle JM, Ramanathan S, et al. Regulation of WASH-dependent actin polymerization and protein trafficking by ubiquitination. *Cell*. Feb 28 2013;152(5):1051-64. doi:10.1016/j.cell.2013.01.051

3.   Hao YH, Fountain MD, Jr., Fon Tacer K, et al. USP7 Acts as a Molecular Rheostat to Promote WASH-Dependent Endosomal Protein Recycling and Is Mutated in a Human Neurodevelopmental Disorder. *Mol Cell*. Sep 17 2015;59(6):956-69. doi:10.1016/j.molcel.2015.07.033

4.   Schaaf CP, Gonzalez-Garay ML, Xia F, et al. Truncating mutations of MAGEL2 cause Prader-Willi phenotypes and autism. *Nat Genet*. Nov 2013;45(11):1405-8. doi:10.1038/ng.2776

5.   Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. *Genet Med*. Jan 2012;14(1):10-26. doi:10.1038/gim.0b013e31822bead0

6.   Fountain MD, Oleson DS, Rech ME, et al. Pathogenic variants in USP7 cause a neurodevelopmental disorder with speech delays, altered behavior, and neurologic anomalies. *Genet Med*. Aug 2019;21(8):1797-1807. doi:10.1038/s41436-019-0433-1

7.   McCarthy J, Lupo PJ, Kovar E, et al. Schaaf-Yang syndrome overview: Report of 78 individuals. *Am J Med Genet A*. Dec 2018;176(12):2564-2574. doi:10.1002/ajmg.a.40650

8.   Fountain MD, Aten E, Cho MT, et al. The phenotypic spectrum of Schaaf-Yang syndrome: 18 new affected individuals from 14 families. *Genet Med*. Jan 2017;19(1):45-52. doi:10.1038/gim.2016.53

9.   Castilla-Vallmanya L, Centeno-Pla M, Serrano M, et al. Advancing in Schaaf-Yang syndrome pathophysiology: from bedside to subcellular analyses of truncated MAGEL2. *J Med Genet*. Sep 7 2022;doi:10.1136/jmg-2022-108690

10.   Capra AP, Agolini E, La Rosa MA, Novelli A, Briuglia S. Correspondence on "Pathogenic variants in USP7 cause a neurodevelopmental disorder with speech delays, altered behavior, and neurologic anomalies" by Fountain et al. *Genet Med*. Feb 2021;23(2):421-422. doi:10.1038/s41436-020-00978-x

11.   Priolo M, Mancini C, Pizzi S, et al. Complex Presentation of Hao-Fountain Syndrome Solved by Exome Sequencing Highlighting Co-Occurring Genomic Variants. *Genes (Basel)*. May 16 2022;13(5)doi:10.3390/genes13050889

12.   Zampieri N, Pulvirenti R, Pedrazzoli E, Camoglio FS. Hao-Fountain syndrome and genital disorders: report of a new possible association. *Ital J Pediatr*. Oct 22 2022;48(1):182. doi:10.1186/s13052-022-01367-7

13.   Zheng H, Mei S, Li F, et al. Expansion of the mutation spectrum and phenotype of USP7-related neurodevelopmental disorder. *Front Mol Neurosci*. 2022;15:970649. doi:10.3389/fnmol.2022.970649

14.   Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. May 2015;17(5):405-24. doi:10.1038/gim.2015.30

15.   Skinner AC, Perrin EM, Skelton JA. Prevalence of obesity and severe obesity in US children, 1999-2014. *Obesity (Silver Spring)*. May 2016;24(5):1116-23. doi:10.1002/oby.21497

16. Lee PA, Chernausek SD, Hokken-Koelega AC, Czernichow P, International Small for
Gestational Age Advisory B. International Small for Gestational Age Advisory Board
consensus development conference statement: management of short children born small
for gestational age, April 24-October 1, 2001. *Pediatrics*. Jun 2003;111(6 Pt 1):1253-61.
doi:10.1542/peds.111.6.1253
17. Group WHOMGRS. WHO Motor Development Study: windows of achievement for six
gross motor development milestones. *Acta Paediatr Suppl*. Apr 2006;450:86-95.
doi:10.1111/j.1651-2227.2006.tb02379.x
18. Dosman CF, Andrews D, Goulden KJ. Evidence-based milestone ages as a framework
for developmental surveillance. *Paediatr Child Health*. Dec 2012;17(10):561-8.
doi:10.1093/pch/17.10.561
19. Butler MG, Miller JL, Forster JL. Prader-Willi Syndrome - Clinical Genetics, Diagnosis
and Treatment Approaches: An Update. *Curr Pediatr Rev*. 2019;15(4):207-244.
doi:10.2174/1573396315666190716120925
20. Schroter J, Dattner T, Hullein J, et al. aRgus: Multilevel visualization of non-
synonymous single nucleotide variants & advanced pathogenicity score modeling for genetic
vulnerability assessment. *Comput Struct Biotechnol J*. 2023;21:1077-1083.
doi:10.1016/j.csbj.2023.01.027
21. Marbach F, Schaaf CP. Response to Briuglia et al. *Genet Med*. Feb 2021;23(2):423-
424. doi:10.1038/s41436-020-00977-y
22. Fountain MD, Schaaf CP. Prader-Willi Syndrome and Schaaf-Yang Syndrome:
Neurodevelopmental Diseases Intersecting at the MAGEL2 Gene. *Diseases*. Jan 13
2016;4(1)doi:10.3390/diseases4010002
23. McCarthy JM, McCann-Crosby BM, Rech ME, et al. Hormonal, metabolic and skeletal
phenotype of Schaaf-Yang syndrome: a comparison to Prader-Willi syndrome. *J Med Genet*.
May 2018;55(5):307-315. doi:10.1136/jmedgenet-2017-105024
24. Angulo MA, Butler MG, Cataletto ME. Prader-Willi syndrome: a review of clinical,
genetic, and endocrine findings. *J Endocrinol Invest*. Dec 2015;38(12):1249-63.
doi:10.1007/s40618-015-0312-9
25. Bennett JA, Germani T, Haqq AM, Zwaigenbaum L. Autism spectrum disorder in
Prader-Willi syndrome: A systematic review. *Am J Med Genet A*. Dec 2015;167A(12):2936-44.
doi:10.1002/ajmg.a.37286
26. Thomason MM, McCarthy J, Goin-Kochel RP, Dowell LR, Schaaf CP, Berry LN.
Neurocognitive and Neurobehavioral Phenotype of Youth with Schaaf-Yang Syndrome. *J*
Autism Dev Disord. Jul 2020;50(7):2491-2500. doi:10.1007/s10803-018-3775-7
27. Curfs LM, Fryns JP. Prader-Willi syndrome: a review with special attention to the
cognitive and behavioral profile. *Birth Defects Orig Artic Ser*. 1992;28(1):99-104.
28. Sijm A, Atlasi Y, van der Knaap JA, et al. USP7 regulates the ncPRC1 Polycomb axis to
stimulate genomic H2AK119ub1 deposition uncoupled from H3K27me3. *Sci Adv*. Nov 4
2022;8(44):eabq7598. doi:10.1126/sciadv.abq7598
29. Qiao H, Tian Y, Huo Y, Man HY. Role of the DUB enzyme USP7 in dendritic
arborization, neuronal migration, and autistic-like behaviors in mice. *iScience*. Jul 15
2022;25(7):104595. doi:10.1016/j.isci.2022.104595

7 Legends

Figure 1: Distribution of USP7 missense and nonsense variant
The known domains and the distribution of missense/nonsense variants along a two-
dimensional representation of the USP7 protein are shown. The size of the points of the
missense variants correlate with the respective REVEL score.

Figure 2: Body measurements of patients with Hao-Fountain Syndrome; one sample t-test
performed for a mean value of 50
A: BMI subdivided by normal weight, overweight, obesity; B: Current measurement
percentiles; C: Birth measurement percentiles

Figure 3: Assessment of severity score values in variable subgroups; Student's t-test and one-
way ANOVA
A: Severity score plotted for sex.; B: Severity score for each type of mutation.; C: Severity
score of missense mutations grouped by localization (Catalytic domain vs. TRAF-like- and
UBL-domain).

Table 1 Novel cases with pathogenic USP7 variants

Table 2 Summary of published and novel cases with pathogenic USP7 variants

Table 3 Developmental/ speech milestones, growth parameters, and IQ of patients with
Hao-Fountain Syndrome

Supplemental figure 1: Body measurements compared by sex
A: BMI values (Student's t-test).; B: Current body measurement percentiles; C: Birth body
measurement percentiles

Supplemental figure 2: Current body measurements compared by genotype
A: BMI values (One-way ANOVA); B: Current body length percentile (One-way ANOVA); C:
Current body weight percentile (One-way ANOVA); D: BMI percentile (One-way ANOVA)

Supplemental figure 3: Birth body measurements compared by sex and genotype
A: Birth body weight percentiles (One-way ANOVA); B: Birth head circumference percentiles
(One-way ANOVA); C: Birth body length percentiles (One-way ANOVA); D: Birth
measurements compared by sex

Supplemental figure 4: Body measurements plotted against age indicating a significant
impact of age on weight percentile (B), BMI percentile (C), and BMI values (C)

614
615 **Supplemental figure 5**: Behavioral traits of Hao-Fountain syndrome patients
616 Several behavioral traits and parental-reported frequency of occurrence ranging from 5
617 (Always) to 1 (Never) (n: 36).
618
Supplemental Figure 6: Severity score QQ plot and assessment for different subgroups
A: QQ plot proofing normal distribution of severity scores within our cohort; B: Severity
score plotted against age of individuals (slope: 0,0004920) indicating no impact of age on
severity; C: Severity score of patients with a truncating mutation plotted for the location of
the predicted location of the truncation; D: Severity score of patients with a missense
mutation plotted for the location of the predicted location of the truncation (Tukey's
multiple comparison test following one-way ANOVA; CD vs. UBL: adjusted p-value = 0.0131)
626
627 **Supplemental Figure 7**: Comparison of three pathogenicity score predictions
628
629 **Supplemental Figure 8:** Statistical comparison of domain-associated pathogenicity scores
630
631 **Supplemental table 1 – Molecular phenotype**: Comprehensive molecular phenotype
632 information on known patients with HAFOUS, including variant coordinates, inheritance, and
633 mutational group allocation, in silico scores, and AMP/ACMG re-classification (all based on
634 NM_003470.3). Novel cases identified as individuals #30-#61.
635
636 **Supplemental table 2 – Behavioral and cognitive profile**: Behavioral phenotypical aspects of
637 all known individuals with HAFOUS, also containing information about cognition (sorted by
638 mutation type).
639
640 **Supplemental table 3 – Motor + speech development**: Milestones in motor and speech
641 development for HAFOUS patients, categorized by mutation type.
642
643 **Supplemental table 4 – Musculoskeletal phenotype**: Musculoskeletal phenotypic features
644 observed in HAFOUS patients, categorized by mutation type.
645
646 **Supplemental table 5 – Neurological phenotype**: Neurological manifestations in HAFOUS
647 patients, sorted by mutation type.
648
649 **Supplemental table 6 – Endocrine phenotype**: Detailed endocrine phenotype of HAFOUS
650 patients, sorted by mutation type.
651
652 **Supplemental table 7 – Respiratory phenotype**: Respiratory phenotype in HAFOUS patients,
653 categorized by mutation type.
654
655 **Supplemental table 8 – Sleep + seizures + EEG**: Sleep patterns, EEG study results, and
656 seizure occurrences in HAFOUS patients, sorted by mutation type.
657

658　**Supplemental table 9 – Eating behavior**: Parental-reported eating behavior of all known
659　individuals with HAFOUS, sorted by mutation type.
660

661　**Supplemental table 10 – Gastrointestinal phenotype**: Gastrointestinal phenotypes in
662　HAFOUS patients, categorized by mutation type.
663

664　**Supplemental table 11 – Body measurements**: Comprehensive body measurements of
665　HAFOUS patients, sorted by mutation type.
666

667　**Supplemental table 12 – Birth and neonatal period**: Phenotypic aspects of the birth and
668　neonatal period in HAFOUS patients, categorized by mutation type.
669

670　**Supplemental table 13 – More phenotypical aspects**: Further phenotypical aspects of
671　HAFOUS patients, sorted by type of mutation. Also containing parental-reported symptoms
672　not being listed in our questionnaire and parental-identified aspects being "most disabling"
673　and "the most striking capability".
674

675　**Supplemental table 14 – Severity score**: Calculation of severity scores for HAFOUS patients
676　meeting missense or truncating mutation criteria within our cohort. Includes points per
677　category, cumulative points, maximum achievable points, and severity scores per individual.

1   **Figures**

3
4
5
6

7   **Figure 1**: Distribution of *USP7* missense and nonsense variants.

8   The known domains and the distribution of missense/nonsense variants along a two-

9   dimensional representation of the USP7 protein are shown. The size of the points of the

10   missense variants correlates with the respective REVEL score.

11
12

13 **Figure 2**: Body measurements of individuals with Hao-Fountain Syndrome; one sample t-test
14 performed for a mean value of 50.
15 A: BMI subdivided by normal weight, overweight, obesity; B: Current measurement centiles;
16 C: Birth measurement centiles

17
18
19 **Figure 3**: Assessment of severity score values in variable subgroups; Student's t-test and one-
20 way ANOVA.
21 A: Severity score plotted for sex; B: Severity score for each type of mutation.; C: Severity
22 score of missense mutations grouped by localization (Catalytic domain vs. TRAF-like- and
23 UBL-domain).

Table 1 Novel cases with pathogenic USP7 variants

Case number	Mutation coordinates	Predicted protein	Inheritance	Type of mutation
30[A]	g.8821978_9123395del		de novo	DEL
31	g.8949646_9109391del		de novo	DEL
32	g.8889561_9051816del		de novo	DEL
33	g.8822840_9053972del		de novo	DEL
34	g.9017053_9035103del		de novo	intragenic DEL
35	g.8915707_8925560del		de novo	intragenic DEL
36	c.238A>T	p.(Arg80*)	de novo	NON
37	c.1157T>A	p.(Leu386*)	de novo	NON
38	c.517dup	p.(Trp173Leufs*3)	de novo	Frameshifting indel
39	c. 786_787del	p.(Arg262Serfs*4)	de novo	Frameshifting indel
40	c.339_340del	p.(Ser114Argfs*10)	de novo	Frameshifting indel
41	c.1794dup	p.(Asn599Glufs*6)	de novo	Frameshifting indel
42	c.3043G>A	p.(Glu1015Lys)	de novo	MISS
43	c.650A>G	p.(Lys217Arg)	de novo	MISS
44[B]	c.3202G>C	p.(Gly1068Arg)	mother and siblings do not carry the mutation	MISS
45	c.1754A>T; c.1691A>C	p.(Asp585Val); p.(Glu564Ala)	de novo	MISS
46	c.3043G>A	p.(Glu1015Lys)	de novo	MISS
47	c.3147G>C	p.(Gln1049His)	unkown	MISS
48	c.841A>G	p.(Lys281Glu)	de novo	MISS
49[C]	c.1258A>G	p.(Lys420Glu)	de novo	MISS
50	c.352T>C	p.(Phe118Leu)	de novo	MISS
51	c.884A>G	p.(Asp295Gly)	de novo	MISS
52	c.490G>A	p.(Asp164Asn)	de novo	MISS
53	c.1175G>C	p.(Gly392Ala)	de novo	MISS
54	c.2021C>T	p.(Ala674Val)	de novo	MISS
55	c.1018C>T	p.(Arg340Trp)	unkown	MISS
56	c.1480A>G	p.(Ile494Val)	unkown	MISS
57[D]	c.2718+5G>A		de novo	SPLIC
58	c.2132_2140+9del		de novo	SPLIC

59	c.721-1G>C		de novo	SPLIC
60	c.1162-8A>G		de novo	SPLIC
61	c.1840-1G>A		de novo	SPLIC

All variants based on NM_003470.3 (hg19)

DEL = Deletion; NON = Nonsense mutation; MISS = Missense mutation; SPLIC = Splice-site mutation

[A]Patient also has a 326 kb duplication at 15a23 including MAP2K and SKOR1 (maternal variant of uncertain significance)

[B]Patient also has a VUS in SIX3, loss of function variants in this gene associated with nonsyndromic holoprosencephaly were described

[C]Patient also has a likely pathogenic variant in TCF20

Table 2 Summary of published and novel cases with pathogenic USP7 variants

Clinical feature	Literature	Our study	Summary	
Muscular hypotonia	16/23	26/30	*42/53*	**79 %**
Oral motor skills delayed/ impaired	6/7	23/31	*29/38*	**76 %**
Altered threshold for pain	6/6	20/28	*26/34*	**76 %**
Gross motor skills delayed/ impaired	6/7	23/32	*29/39*	**74 %**
ASD	14/18	17/25	*31/43*	**72 %**
Fine motor skills delayed/ impaired	5/6	20/31	*25/37*	**68 %**
Brain MRI anomalies	26/21	7/13	*23/34*	**68 %**
Abnormal gait	8/17	23/30	*31/47*	**66 %**
Limited communication skills	2/6	22/31	*24/37*	**65 %**
Neonatal hypotonia	10/20	15/24	*25/44*	**57 %**
Dental issues	4/6	16/30	*20/36*	**56 %**
Feeding difficulties	14/22	16/32	*30/54*	**56 %**
Chronic constipation/ diarrhea	14/20	15/32	*29/52*	**56 %**
Eye anomalies	17/25	11/28	*28/53*	**53 %**
Complications during pregnancy	3/8	17/30	*20/38*	**53 %**
ADHD	7/17	14/25	*21/42*	**50 %**
Sleep disturbances	7/18	15/29	*22/47*	**47 %**
Eating difficulties	4/7	12/29	*12/36*	**44 %**
Temperature instabilities	2/4	12/30	*14/34*	**41 %**
Small feet	7/21	12/25	*19/46*	**41 %**
Complications during delivery	2/6	13/31	*15/37*	**41 %**
Congenital anomalies	2/5	12/29	*14/34*	**41 %**
Seizures	13/27	10/30	*23/57*	**40 %**
Neonatal poor suck	6/19	14/31	*20/50*	**40 %**
Hyperphagia	1/5	13/31	*14/36*	**39 %**
Incontinence	3/6	12/32	*15/38*	**39 %**
GERD	10/19	8/30	*18/49*	**37 %**
Behavioral problems	2/5	8/24	*10/29*	**34 %**
Small hands	8/21	6/22	*14/43*	**33 %**
Scoliosis/ Kyphosis	7/20	7/27	*14/47*	**30 %**
Sleep apnea	2/6	8/28	*10/34*	**29 %**
Gaining weight difficulties	7/19	8/32	*15/51*	**29 %**
Contractures	7/19	4/26	*11/45*	**24 %**
Hypogonadism	7/19	4/28	*11/47*	**23 %**
SGA	4/7	4/29	*8/36*	**22 %**
EEG anomalies	1/5	3/15	*4/20*	**20 %**

Skin picking	4/22	5/30	*9/52*	**17 %**
LGA	0/7	6/29	*6/36*	**17 %**
Short stature	4/19	2/29	*6/48*	**13 %**
GH deficiency	2/4	0/20	*2/24*	**8 %**

Table 3 Developmental/ speech milestones, growth parameters, and IQ of patients with Hao-Fountain Syndrome

	Mean value	Expected value (normal population)	Assessed individuals (*n*)
First spoken word	**21,1** months	18 months	*30*
First combining words	**32,9** months	24 months	*24*
Sit w/o support	**11,7** months	6 months	*46*
Crawl	**14,3** months	12 months	*27*
Walk w/o support	**26,6** months	15 months	*47*
FSIQ	**78,30**	100	*10*
Body weight percentile	**58,35**	50	*39*
Body length percentile	**59,23**	50	*38*
BMI	**18,84**	depends on age	*36*
BMI percentile	**60,63**	50	*34*
Birth weight percentile	**41,19**	50	*36*
Birth length percentile	**46,67**	50	*38*